Particulate materials
AssigneeNektar Therapeutics
InventorsPeter York, Boris Yu Shekunov, Mahboob Ur Rehman, Jane Catherine Feeley
Life of this patent
Estimating the term…
Abstract
The present invention relates to active substances in particulate form, to methods for preparing them and to their uses. The present invention provides particulate powders, such as might be of use for delivery using a dry powder inhaler (DPI) or similar delivery device, having properties which may be beneficial to the DPI delivery process.
Claims44
An active substance in particulate form suitable for administration via a dry powder inhaler, the particulates comprising:
- a volume mean aerodynamic diameter of less than 7 microns;
- a bulk powder density within a range from about 0.1 g/cm3 to about 0.5 g/cm3;
- and
- a surface-to-volume ratio of at least 2.5 times that of spherical particles of a corresponding volume diameter, wherein the particulates are solid, non-hollow, non-porous particles and the active substance is selected from the group consisting of insulin, pro-insulin, mono-acylated insulin, insulinotropin, and insulin-like growth factor.
An active substance in particulate form suitable for administration via a dry powder inhaler, the particulates comprising:
- a volume mean aerodynamic diameter of less than 7 microns;
- a bulk powder density within a range from about 0.1 g/cm3 to about 0.5 g/cm3;
- and
- a surface-to-volume ratio of at least 2.5 times that of spherical particles of a corresponding volume diameter, wherein the particulates are solid, non-hollow, non-porous particles and the active substance is selected from the group consisting of amphotericin-B, parathyroid hormone, glucagon-like peptide, and an anti-infective agent.
An active substance in particulate form suitable for administration via a dry powder inhaler, the particulates comprising:
- a volume mean aerodynamic diameter of less than 7 microns;
- a bulk powder density within a range from about 0.1 g/cm3 to about 0.5 g/cm3;
- and
- a surface-to-volume ratio of at least 2.5 times that of spherical particles of a corresponding volume diameter, wherein the particulates are solid, non-hollow, non-porous particles and the active substance is selected from the group consisting of salbutamol, terbutalene, salmeterol, fenoterol, and bromocriptine.
Dependencies are inferred from the claim text.